Side-effects Profile and Outcomes of Ponatinib in the Treatment of Chronic Myeloid Leukemia
Document Type
Article
Publication Date
2020
Abstract
Ponatinib is associated with cardiovascular adverse events (CAEs), and its frequency in the real world is limited. In this retrospective study, we examined the survival outcomes and associated toxicities in 78 consecutive ponatinib-treated patients with chronic myeloid leukemia (CML) at the Moffitt Cancer Center from January 2011 through December 2017. The most common non-CAE was thrombocytopenia (39.7%), occurring in a dose-dependent fashion. Eighteen patients (23.1%) experienced some form of CAE, with the most common being arrhythmia (9%) and hypertension (7.7%), whereas 3 patients experienced myocardial infarction (3.8%). Before 2014, most patients were started on ponatinib 45 mg daily. There was an inverse correlation between cardio-oncology referral and the number of CAEs (P = .0440); however, a lower ponatinib starting dose, more frequent dose reduction, and increased cardio-oncology referral all were likely to have contributed to the observed decrease in CAEs after 2014. The response rate and 5-year overall survival (OS) were higher than those observed in the Ponatinib Ph+ ALL and CML Evaluation (PACE) trial (major molecular response, 58.7% vs 40% and OS, 76% vs 73%; median follow-up of 32.5 months). Ponatinib-treated patients with chronic phase–CML did not show a significant improvement with allogeneic stem cell transplantation, whereas those with accelerated phase/blast phase–CML had a much better outcome (median OS of 32.9 months vs 9.2 months; P = .01). These results demonstrate that ponatinib is highly effective. Dose adjustments and increased awareness of the cardiotoxicities associated with ponatinib may help maximize its benefits.
Digital Object Identifier (DOI)
https://doi.org/10.1182/bloodadvances.2019000268
Citation / Publisher Attribution
Blood Advances, v. 4, issue 3, p. 530-538,
Scholar Commons Citation
Chan, Onyee; Talati, Chetasi; Isenalumhe, Leidy; Shams, Samantha; Nodzon, Lisa; Fradley, Michael; Sweet, Kendra; and Pinilla-Ibarz, Javier, "Side-effects Profile and Outcomes of Ponatinib in the Treatment of Chronic Myeloid Leukemia" (2020). Oncologic Sciences Faculty Publications. 7.
https://digitalcommons.usf.edu/onc_facpub/7
Was this content written or created while at USF?
Yes
